Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

However, in the glass box approach, the raw and timestamped data (such as physiological signals like ECG, temperature, or ...

War in the Middle East disrupts pharmaceutical supply chains in the Gulf region, forcing drugmakers to reroute shipments of ...

Sentynl, a subsidiary of Zydus Lifesciences, entered into a licensing agreement with PRG S&T for Progerinin (SLC-D011), an ...

Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, discusses FDA's shift to a single pivotal trial standard, in an effort to streamline drug development without lowering ...

In 2025 it seemed the only certainty for biotech was more uncertainty. Biotech leaders conducted business as usual against ...

Novo Nordisk issued a response to an FDA warning letter that cited serious violations in how the company tracked and reported ...

In today's Pharmaceutical Executive Daily, Senate Democrats press major pharmaceutical companies for transparency on the ...

In today’s Pharmaceutical Executive Daily, Vinay Prasad exits the FDA’s Center for Biologics Evaluation and Research for the ...

While regulatory alignment remains essential, operational urgency driving companies to AI adoption is equally profound. In ...

Testing identified significant impurity formation when tirzepatide is compounded with B12 variants, suggesting chemical incompatibility that is not evaluated under FDA review pathways. Uncertainty ...

The second exit in under a year follows controversy around CRLs for Replimune and Capricor, including criticism that mid- and ...